The role of opioid kappa1 and kappa2 receptors in reperfusion cardiac injury was studied. Male Wistar rats were subjected to a 45-min coronary artery occlusion followed by a 120-min reperfusion. Opioid kappa receptor agonists were administered intravenously 5 min before the onset of reperfusion, while opioid receptor antagonists were given 10 min before reperfusion. The average value of the infarct size/area at risk (IS/AAR) ratio was 43 - 48% in untreated rats. Administration of the opioid kappa1 receptor agonist (-)-U-50,488 (1 mg/kg) limited the IS/AAR ratio by 42%. Administration of the opioid kappa receptor agonist ICI 199,441 (0.1 mg/kg) limited the IS/AAR ratio by 41%. The non-selective opioid kappa receptor agonist (+)-U-50,488 (1 mg/kg) with low affinity for opioid kappa receptor, the peripherally acting opioid kappa2 receptor agonist ICI 204,448 (4 mg/kg) and the selective opioid ?2 receptor agonist GR89696 (0.1 mg/kg) had no effect on the IS/AAR ratio. Pretreatment with naltrexone, the peripherally acting opioid receptor antagonist naloxone methiodide, or the selective opioid kappa2 receptor antagonist nor-binaltorphimine completely abolished the infarct-reducing effect of (-)-U-50,488 and ICI 199,441. Pretreatment with the selective opioid ? receptor antagonist TIPP[psi] and the selective opioid µ receptor antagonist CTAP did not alter the infarct reducing effect of (-)-U-50,488 and ICI 199,441. Our study is the first to demonstrate the following: (a) the activation of opioid kappa2 receptor has no effect on cardiac tolerance to reperfusion; (b) peripheral opioid kappa1 receptor stimulation prevents reperfusion cardiac injury; (c) ICI 199,441 administration resulted in an infarct-reducing effect at reperfusion; (e) bradycardia induced by opioid kappa receptor antagonists is not dependent on the occupancy of opioid kappa receptor.

Laboratory of Experimental Cardiology Cardiology Research Institute Tomsk National Research Medical Center the Russian Academy of Sciences Tomsk Russia

Zobrazit více v PubMed

BARLOW JJ, BLACKBURN TP, COSTELLO GF, JAMES R, LE COUNT DJ, MAIN BG, PEARCE RJ, RUSSELL K, SHAW JS. Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted-ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists. J Med Chem. 1991;34:3149–3158. doi: 10.1021/jm00115a001. PubMed DOI

BIRCH PJ, ROGERS H, HAYES AG, HAYWARD NJ, TYERS MB, SCOPES DIC, NAYLOR A, JUDD DB. Neuroprotective actions of GR89696, a highly potent and selective κ-opioid receptor agonist. Br J Pharmacol. 1991;103:1819–1823. doi: 10.1111/j.1476-5381.1991.tb09869.x. PubMed DOI PMC

CHENG J, ROQUES BP, GACEL GA, HUANG E, PASTERNAK GW. κ3 Opiate receptor binding in the mouse and rat. Eur J Pharmacol. 1992;226:15–20. doi: 10.1016/0922-4106(92)90077-9. PubMed DOI

EITEL I, WANG J, STIERMAIER T, FUERNAU G, FEISTRITZER HJ, JOOST A, JOBS A, MEUSEL M, BLODAU C, DESCH S, DE WAHA-THIELE S, LANGER H, THIELE H. Impact of morphine treatment on infarct size and reperfusion injury in acute reperfused ST-elevation myocardial infarction. J Clin Med. 2020;9:735. doi: 10.3390/jcm9030735. PubMed DOI PMC

FABRIS E, KILIC S, SCHELLINGS DAAM, BERG JM, KENNEDY MW, VAN HOUWELINGEN KG, GIANNITSIS E, KOLKMAN E, OTTERVANGER JP, HAMM C, VAN’T HOF AWJ. Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. Heart. 2017;103:1515–1520. doi: 10.1136/heartjnl-2017-311181. PubMed DOI

GUO HT, ZHANG RH, ZHANG Y, ZHANG L-J, LI J, SHI Q-X, WANG Y-M, FAN R, BI H, YIN W, PEI J-M. Endogenous κ-opioid peptide mediates the cardioprotection induced by ischemic postconditioning. J Cardiovasc Pharmacol. 2011;58:207–215. doi: 10.1136/hrt.2010.208967.152. PubMed DOI

HORAN PJ, DE COSTA BR, RICE K, HAASETH RC, HRUBY VJ, PORRECA F. Differential antagonism of bremazocine- and U-69,593-induced antinociception by quadazocine: further functional evidence of opioid k receptor multiplicity in the mouse. J Pharmacol Exp Ther. 1993;266:926–933. PubMed

HWANG D, KIM HK, LEE JM, CHOI KH, KIM J, RHEE T-M, PARK J, PARK TK, YANG JH, SONG YB, CHOI J-H, HAHN J-Y, CHOI S-H, KOO B-K, KIM YJ, CHAE SC, CHO MS, KIM SJ, GWON H-C, JEONG MH, KIM H-S KAMIR Investigators. Effects of statin intensity on clinical outcome in acute myocardial infarction patients. Circ J. 2018;82:1112–1120. doi: 10.1253/circj.cj-17-1221. PubMed DOI

LISHMANOV AY, MASLOV LN, LASUKOVA TV, CRAWFORD D, WONG TM. Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and KATP channels. Bull Exp Biol Med. 2007;143:187–190. doi: 10.1007/s10517-007-0046-6. PubMed DOI

MASLOV LN, BARBARASH OL. Pharmacological approaches to limiting the size of myocardial infarction in patients with acute myocardial infarction: Analysis of clinical data. Eksp Klin Farmakol. 2018;81:34–41. https://doi.org/0.30906/0869-2092-2018-81-3-34-41 .

MASLOV LN, KHALIULIN I, OELTGEN PR, NARYZHNAYA NV, PEI J-M, BROWN SA, LISHMANOV YB, DOWNEY JM. Prospects of creation of cardioprotective and antiarrhythmic drugs based on opioid receptor agonists. Med Res Rev. 2016;36:871–923. doi: 10.3410/f.726370322.793534522. PubMed DOI PMC

MASLOV LN, LISHMANOV YB. The anti-arrhythmic effect of D-Ala2, Leu5, Arg6-enkephalin and its possible mechanism. Int J Cardiol. 1993;40:89–94. doi: 10.1016/0167-5273(93)90269-m. PubMed DOI

MASLOV LN, LISHMANOV YUB, OELTGEN PR, BARZAKH EI, KRYLATOV AV, GOVINDASWAMI M, BROWN SA. Activation of peripheral δ2 opioid receptors increases cardiac tolerance to ischemia/reperfusion injury: Involvement of protein kinase C, NO-synthase, KATP channels and the autonomic nervous system. Life Sci. 2009;84:657–663. doi: 10.1016/j.lfs.2009.02.016. PubMed DOI

MASLOV LN, NARYZHNAYA NV, TSIBULNIKOV SYU, KOLAR F, ZHANG Y, WANG H, GUSAKOVA AM, LISHMANOV YB. Role of endogenous opioid peptides in the infarct size-limiting effect of adaptation to chronic continuous hypoxia. Life Sci. 2013;93:373–379. doi: 10.1016/j.lfs.2013.07.018. PubMed DOI

NECKAR J, PAPOUSEK F, NOVAKOVA O, OSTADAL B, KOLAR F. Cardioprotective effects of chronic hypoxia and ischaemic preconditioning are not additive. Basic Res Cardiol. 2002;97:161–167. doi: 10.1007/s003950200007. PubMed DOI

PEART JN, GROSS ER, GROSS GJ. Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction. J Cardiovasc Pharmacol. 2004;43:410–415. doi: 10.1097/00005344-200403000-00012. PubMed DOI

PEART JN, GROSS ER, REICHELT ME, HSU A, HEADRICK JP, GROSS GJ. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res Cardiol. 2008;103:454–463. doi: 10.1007/s00395-008-0726-z. PubMed DOI

PUGSLEY MK, PENZ WP, WALKER MJ, WONG TM. Cardiovascular actions of the κ-agonist, U-50,488H, in the absence and presence of opioid receptor blockade. Br J Pharmacol. 1992;105:521–526. doi: 10.1111/j.1476-5381.1992.tb09012.x. PubMed DOI PMC

ROTHMAN RB, BYKOV V, XUE BG, XU H, DE COSTA BR, JACOBSON AE, RICE KC, KLEINMAN JE, BRADY LS. Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences. Peptides. 1992;13:977–987. doi: 10.1016/0196-9781(92)90059-c. PubMed DOI

SANDER GE, LOWE RF, GILES TD. The effects of barbiturates upon the hemodynamic responses to intravenous methionine-enkephalin in dogs: modulation by the GABA complex. Peptides. 1986;7:259–265. doi: 10.1016/0196-9781(86)90223-8. PubMed DOI

SCHULTZ JJ, HSU AK, GROSS GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (δ)-opioid receptor in the intact rat heart. J Mol Cell Cardiol. 1997;29:2187–2195. doi: 10.1006/jmcc.1997.0454. PubMed DOI

SHAW JS, CARROLL JA, ALCOCK P, MAIN BG. ICI 204448: a kappa-opioid agonist with limited access to the CNS. Br J Pharmacol. 1989;96:986–992. doi: 10.1111/j.1476-5381.1989.tb11911.x. PubMed DOI PMC

SKRABALOVA J, NECKAR J, HEJNOVA L, BARTONOVA I, KOLAR F, NOVOTNY J. Antiarrhythmic effect of prolonged morphine exposure is accompanied by altered myocardial adenylyl cyclase signaling in rats. Pharmacol Rep. 2012;64:351–359. doi: 10.1016/s1734-1140(12)70775-2. PubMed DOI

VENTURA C, BASTAGLI L, BERNARDI P, CALDARERA CM, GUARNIERI C. Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim Biophys Acta. 1989;987:69–74. doi: 10.1016/0005-2736(89)90456-2. PubMed DOI

VENTURA C, SPURGEON H, LAKATTA EG, GUARNIERI C, CAPOGROSSI MC. Kappa and delta opioid receptor stimulation affects cardiac myocyte function and Ca2+ release from an intracellular pool in myocytes and neurons. Circ Res. 1992;70:66–81. doi: 10.1161/01.res.70.1.66. PubMed DOI

WONG GT, YAO L, XIA Z, IRWIN MG. Intrathecal morphine remotely preconditions the heart via a neural pathway. J Cardiovasc Pharmacol. 2012;60:172–178. doi: 10.1097/fjc.0b013e31825e2195. PubMed DOI